Accuray Radixact® System with Synchrony® Technology Delivers Advanced Cancer Treatments at Multiple Hospitals in Japan

Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) has announced that several leading hospitals in Japan are now utilizing its Radixact® System combined with Synchrony® Automatic, Real-time Motion Synchronization Technology for advanced cancer treatments. This technology allows more precise treatment of tumors that move, reducing radiation exposure to healthy tissue. Notably, Takarazuka City Hospital treated the first Synchrony patient in Asia and was the first globally to perform a liver treatment with this technology. The adoption of these systems in Japan, which has the highest penetration of such innovations, aims to enhance cancer care and treatment outcomes.

Positive

• Radixact System and Synchrony technology enhance the delivery of cancer treatment, improving accuracy and reducing harm to healthy tissues.
• Hospitals in Japan, including Takarazuka City Hospital, are early adopters, indicating strong market acceptance.
• Increased treatment capabilities including image-guided and stereotactic body radiation therapy expansion.

Negative

• None.

SUNNYVALE, Calif., Sept. 17, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that leading hospitals in Japan are using the Radixact^® System with the Synchrony^® Automatic, Real-time Motion Synchronization Technology¹ to provide advanced cancer treatments to more patients throughout the country. The addition of Synchrony to the Radixact System will enable the hospital teams to efficiently deliver highly accurate radiation dose to tumors that move as a result of bodily processes or patient movement, minimizing the amount of healthy tissue surrounding the tumors that are exposed to high-dose radiation, all while patients breathe naturally – no uncomfortable patient restraints or breath-hold techniques are required. Synchrony is the only technology using image guidance during radiation delivery to automatically synchronize radiation treatment in real-time with the movement of the tumor.

Multiple sites in Japan are now using the Radixact System with Synchrony, including Takarazuka City Hospital in Hyogo, Japanese Red Cross Nagoya Daini Hospital in Aichi, and Kishiwada Tokushukai Hospital in Osaka. The Synchrony technology will enable the hospital teams to treat a wider range of cancer cases, faster and with less harm to patients. The Takarazuka City Hospital team treated the first Synchrony patient in Asia, and was also the first in the world to perform a liver treatment with the innovative technology.

Japanese Red Cross Nagoya Daini Hospital replaced an existing TomoTherapy^® System with the next-generation Radixact System. The hospital team, in partnership with Nagoya City University, led by Prof. Yuta Shibamoto, is using the system and the Synchrony technology to expand cancer treatment capabilities and help improve patients' outcomes.

"Using the Radixact System with Synchrony real-time tracking technology, SBRT at our hospital can be performed more effectively in the lower lobes of the lung. Synchrony enables us to reduce radiation exposure to healthy lung tissues in the lower lobe, because we no longer have to expand the treatment field to encompass the entire volume of tumor movement. I can confidently recommend Radixact with Synchrony to our patients," said Chikao Sugie, M.D., Vice Director of Department of Radiology at Japanese Red Cross Nagoya Daini Hospital. "The introduction of the Radixact System with Synchrony allows us to decrease the irradiated lung volume, making the treatment less stressful and invasive for patients, while also reducing the procedural burden on our healthcare team. In the future, I would like to expand the indications for treatment using this technology to include liver SBRT, based on our positive experience with lung SBRT and boost irradiation of advanced lung tumors. Synchrony technology has increased the versatility of the system and achieved automated, ultra-precise radiation therapy, which brings exceptional value to us."

"We are very encouraged by the early adoption of our Synchrony and Radixact System technologies by customers in Japan, the country currently with the highest penetration of these innovative solutions in the world. We are proud to have the opportunity to partner with such enthusiastic clinical professionals to advance cancer care in Japan," said Suzanne Winter, chief commercial officer and senior vice president, R&D at Accuray. "Cancer is highly prevalent in the aging Japanese population. Synchrony for the Radixact System will provide clinicians with the technology they need to effectively and efficiently treat virtually any patient requiring radiation therapy. The combined technologies enable the delivery of radiation using a variety of methods — from image-guided intensity-modulated radiation therapy (IG-IMRT) to stereotactic body radiation therapy (SBRT) — to treat almost any tumor, even those that move, with precision, accuracy and unprecedented flexibility."

Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and sells radiation therapy systems that are intended to make cancer treatments shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives. Our radiation treatment delivery systems in combination with fully-integrated software solutions set the industry standard for precision and cover the full range of radiation therapy and radiosurgery procedures. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.

Safe Harbor Statement 
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com

¹"Synchrony^® Automatic, Real-time Motion Synchronization Technology" is synonymous with the development name: "Motion Tracking and Compensation Feature for the Radixact^® Treatment Delivery System"

View original content to download multimedia:http://www.prnewswire.com/news-releases/accuray-radixact-system-with-synchrony-technology-delivers-advanced-cancer-treatments-at-multiple-hospitals-in-japan-301132962.html

SOURCE Accuray Incorporated

FAQ

What is the significance of the Radixact System with Synchrony technology for cancer treatment in Japan?

The Radixact System with Synchrony technology allows for more precise radiation therapy, effectively treating moving tumors while minimizing damage to surrounding healthy tissue.

Which hospitals in Japan are using Accuray's Radixact System?

Prominent hospitals include Takarazuka City Hospital, Japanese Red Cross Nagoya Daini Hospital, and Kishiwada Tokushukai Hospital.

What recent developments have occurred regarding the Radixact System in Asia?

Takarazuka City Hospital treated the first Synchrony patient in Asia, marking a significant milestone for Accuray's technology.

How does the Synchrony technology improve patient outcomes?

Synchrony technology facilitates real-time tracking and reduces the radiation volume needed, making treatments less invasive and stressful for patients.

What are the future prospects for Accuray's technology in Japan?

There are plans to expand treatment applications, including the use of Synchrony technology for liver treatments, based on positive results from lung treatments.